Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9896847 | 1.00 | KDM4E (0.33) | KDM4EALDH1A1CHRM2CHRM4CHRM5 | |
| SCHEMBL9897265 | 0.89 | CHRM2 (0.39) | KDM4EALDH1A1CHRM2CHRM4CHRM5 | |
| SCHEMBL735350 | 0.82 | DNM1 (0.36) | KDM4EALDH1A1SMN1; SMN2CA12CA2 | |
| N,N-Dimethylethanaminium SCHEMBL4448989 | 0.78 | — | — | |
| SCHEMBL10004329 | 0.78 | KDM4E (0.32) | KDM4EALDH1A1CHRM2CHRM4CHRM5 | |
| Trimethylammonium SCHEMBL4265011 | 0.78 | — | — | |
| SCHEMBL9898539 | 0.77 | CHRM2 (0.34) | ALDH1A1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL9898057 | 0.77 | CHRM2 (0.34) | ALDH1A1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL16389911 | 0.75 | — | — | |
| SCHEMBL35885 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471798-B1 | PROCESS FOR PRODUCTION OF SILANE COUPLING AGENTS | BRIDGESTONE CORP (JP) | 2015-08-19 | — | — | EP | claimed |
| EP-2471798-A1 | PROCESS FOR PRODUCTION OF SILANE COUPLING AGENTS | Bridgestone Corporation (JP) | 2012-07-04 | — | — | EP | claimed |
| US-20120149929-A1 | PROCESS FOR PRODUCING SILANE COUPLING AGENT | BRIDGESTONE CORPORATION (JP) | 2012-06-14 | — | — | US | claimed |
| US-9150595-B2 | Process for producing silane coupling agent | BRIDGESTONE CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| EP-2471798-B1 | PROCESS FOR PRODUCTION OF SILANE COUPLING AGENTS | BRIDGESTONE CORP (JP) | 2015-08-19 | — | — | EP | disclosed |
| EP-2471798-A1 | PROCESS FOR PRODUCTION OF SILANE COUPLING AGENTS | Bridgestone Corporation (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149929-A1 | PROCESS FOR PRODUCING SILANE COUPLING AGENT | BRIDGESTONE CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149929-A1 | PROCESS FOR PRODUCING SILANE COUPLING AGENT | HAO2, SAMM50, SKP2 | KDM4E 1334/4885ALDH1A1 1369/4885CHRM2 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.